Clinical trials: Community-acquired Pneumonia (CAP)
Community-acquired Pneumonia
pedCAPNETZ - Community Acquired Pneumonia (CAP) in Childhood and Adolescence
Establishment of a study network and patient cohort for pediatric CAP
- Trial name
- pedCAPNETZ (NCT04047108)
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- Hannover Medical School
Community Acquired Pneumonia (CAP), Community Acquired Pneumonia
Comparing Antibiotic Treatment Strategies for Children With Pneumonia in Outpatient Settings: (STAMPP)
The goal of this clinical trial is to determine if a "watch and wait" antibiotic strategy, called Safety Net Antibiotic Prescribing (SNAP), can safely reduce unnecessary antibiotic use while ensuring that children diagnosed with…
- Trial name
- STAMPP (NCT06986148)
- Testing
- Immediate Antibiotic Prescribing Group Instructions, Safety Net Antibiotic Prescribing (SNAP) Group Instructions
- Where
- 4 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Pneumonia, Community-Acquired Infections
Helmet Continuous Positive Airway Pressure Versus Oxygen Venturi in Acute Respiratory Failure in CAP: CAPOVeRSO
The purpose of this study is to compare the efficacy of CPAP application by a helmet and O2 administration by a Venturi mask in terms of gas exchanges improvement in patients with acute respiratory failure due to…
- Conditions
- Pneumonia, Community-Acquired Infections, Respiratory Insufficiency, Acute Lung Injury
- Trial name
- CAPOVeRSO (NCT00603564)
- Testing
- Castar Starmed (CPAP) delivered by a helmet
- Where
- Italy
- Volunteers
- 47 people
- Sponsor
- University of Milan
Community-acquired Pneumonia
A Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin in Treating CAP
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of intravenous nemonoxacin compared with intravenous moxifloxacin in adult patients with community-acquired pneumonia (CAP).
- Trial name
- NCT02205112
- Testing
- Nemonoxacin, Levofloxacin
- Where
- 63 sites in China, Taiwan
- Volunteers
- 598 people
- Sponsor
- TaiGen Biotechnology Co., Ltd.
Community-Acquired Bacterial Pneumonia (CABP)
Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia
The purpose of this study is to determine the efficacy, safety and tolerability of JNJ-32729463 compared to moxifloxacin for the treatment of subjects requiring hospitalization for Community-Acquired Bacterial Pneumonia (CABP).
- Trial name
- NCT01198626
- Testing
- JNJ-32729463, moxifloxacin, JNJ-32729463 (Open-Label)
- Where
- 34 sites in United States, Canada and 4 more
- Volunteers
- 32 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Community Acquired Pneumonia (CAP)
Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia
Aim: Demonstrate the equivalent efficacy and superior safety of Ceftriaxone 1 gram daily compared with Ceftriaxone 2 grams daily among hospitalized patients with community-acquired pneumonia who are not admitted to the intensive…
- Trial name
- DC-CAP (NCT07537413)
- Testing
- Ceftriaxone 1 gram daily, Ceftriaxone 2 grams daily
- Where
- 4 sites in United States
- Volunteers
- 900 people
- Sponsor
- University of Maryland, Baltimore
Community-acquired Pneumonia
A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP
A Phase 1b/2a, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Plasma gelsolin (rhu-pGSN) Added to Standard of Care in Subjects…
- Trial name
- NCT03466073
- Testing
- Recombinant Human Plasma Gelsolin
- Where
- 8 sites in Australia, Georgia
- Volunteers
- 33 people
- Sponsor
- BioAegis Therapeutics Inc.
Pneumonia
Community-Acquired Pneumonia (CAP) Surveillance
Prospective, non-interventional, multi-center study. 7 investigative centers will involved in China. Around 560 CAP outpatients or inpatients will be screened until 56 M. pneumoniae isolates collected.
- Trial name
- NCT01416506
- Testing
- No Drug
- Where
- China
- Volunteers
- 560 people
- Sponsor
- Bayer
Community Acquired Pneumonia (CAP)
Chest Radiography Versus Ultra-Low-Dose Chest Computed Tomography in Adults in the Emergency Department
Objective: To quantify and compare total staff person-time per imaging episode betweenconventional chest radiography (CXR) and ULDCT in adult emergency department patients in whom CAP is a differential diagnosis.
- Trial name
- TIME-CAP (NCT07870525)
- Testing
- ULDCT
- Where
- Denmark
- Volunteers
- 66 people
- Sponsor
- University of Southern Denmark
Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum
Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)
This Phase 2 study tests whether adding two immune therapies - nogapendekin alfa-inbakicept (NAI) and off-the-shelf iNKT cell infusions - to standard care can safely help critically ill adults with severe community-acquired…
- Conditions
- Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum, Sepsis, Lymphopenia / Immunoparalysis in Critically Ill Adults
- Trial name
- NCT07492888
- Testing
- Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797)
- Sponsor
- ImmunityBio, Inc.
Community-Acquired Pneumonia (CAP)
Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia
A trial in which patients over 18 years of age who are hospitalized with community acquired pneumonia and are otherwise eligible for entry into the study are randomly selected to receive one of two treatment regimens.
- Trial name
- NCT00035347
- Testing
- IV azithromycin, ceftriaxone, oral azithromycin
- Where
- 37 sites in United States, Canada and 3 more
- Volunteers
- 219 people
- Sponsor
- Pfizer
Pneumonia
P4 Peptide in Community Acquired Pneumonia
The investigators' aim is to find out whether immune cells from patients with a severe chest infection will react ex vivo to a new immunomodulating peptide, P4 as part of augmented passive immunotherapy The investigators know…
- Trial name
- P4 (NCT03497962)
- Testing
- Venepuncture, Bronchoscopy
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Liverpool University Hospitals NHS Foundation Trust
Community-acquired Pneumonia
Santeon-CAP; Dexamethasone in Community-acquired Pneumonia
The present study is designed to investigate the beneficial effects of adjunctive dexamethasone therapy in patients admitted with community-acquired pneumonia, additionally aiming at assessing what patients benefit from…
- Trial name
- NCT01743755
- Testing
- Dexamethasone
- Where
- 4 sites in Netherlands
- Volunteers
- 413 people
- Sponsor
- St. Antonius Hospital
Pneumonia
Pulmonary Infections Masquerading as Community-Acquired Pneumonia
The purpose of this research is to identify cases from patients who have been referred for consultation to the Infectious Disease Section at the VAMC, Houston, and to compare them with other cases of CAP in order to determine…
- Trial name
- NCT00304395
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Michael E. DeBakey VA Medical Center
Community-acquired Pneumonia, Severe Pneumonia
Fulminant Severe CAP - an Observational Study
Severe community-acquired pneumonia (CAP) represents a major cause of hospital mortality. Among severe CAP cases, some exhibit a rapidly progressive evolution, leading to severe ARDS/acute respiratory failure and septic shock…
- Conditions
- Community-acquired Pneumonia, Severe Pneumonia, ARDS, Human, Sepsis
- Trial name
- FULMISCAP (NCT06516601)
- Testing
- no intervention
- Where
- 2 sites in Italy
- Volunteers
- 1,460 people
- Sponsor
- University of Trieste
Pneumonia
A Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin in Subjects With Community-acquired Pneumonia
The purpose of this study is to assess if a therapy with oral and intravenous moxifloxacin is as effective as a therapy with intravenous ceftriaxone + intravenous azithromycin followed by oral amoxicilline/clavulanate and oral…
- Trial name
- NCT00717561
- Testing
- Avelox (Moxifloxacin, BAY12-8039), Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin
- Where
- 23 sites in Italy
- Volunteers
- 60 people
- Sponsor
- Bayer
Community-acquired Pneumonia, CAP
Inhaled Lexofloxacin vs Usual Care for Treatment of Community-Acquired Pneumonia
This trial aims to determine whether treatment with inhaled levofloxacin (an antibiotic) is equal to systemic antibiotic treatment (usual care) for patients admitted to a hospital with community-acquired pneumonia in regards to…
- Conditions
- Community-acquired Pneumonia, CAP, Community Acquired Pneumonia, Pneumonia
- Trial name
- LANDCAP 2 (NCT07843017)
- Testing
- Inhaled levofloxacin, Standard-of-care / Usual care
- Volunteers
- 460 people
- Sponsor
- Copenhagen Respiratory Research
Community-acquired Bacterial Pneumonia
Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia
This study will evaluate the safety and efficacy of an experimental antibiotic, solithromycin, in the treatment of adult patients with community-acquired pneumonia.
- Trial name
- SOLITAIRE-IV (NCT01968733)
- Testing
- Solithromycin, Moxifloxacin
- Where
- 270 sites in United States, Argentina and 24 more
- Volunteers
- 863 people
- Sponsor
- Melinta Therapeutics, Inc.
Community-acquired Pneumonia
Oral Nemonoxacin in Treating Elderly Patients With CAP
This study was to evaluate the safety and efficacy of oral nemonoxacin in treating elderly patients (aged ≥ 65 years) with community-acquired pneumonia (CAP).
- Trial name
- NCT05133752
- Testing
- Nemonoxacin
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- TaiGen Biotechnology Co., Ltd.
Pneumonia
Costs, Health Status and Outcomes of CAP (Community-Acquired Pneumonia)
The purpose of this study is to collect additional data on hospitalized Community-Acquired Pneumonia (CAP) on health states, health outcomes and on (health) resources and estimate the differences in the quality of life and…
- Trial name
- CHO-CAP (NCT00812084)
- Where
- Netherlands
- Volunteers
- 48,634 people
- Sponsor
- UMC Utrecht